|
The
newly launched European Partnership for Personalised Medicine (EP
PerMed) aims to improve future healthcare for all citizens through
personalised therapy, diagnosis and prevention. With a total budget
of around €375 million, provided by the EU and more than 50
international partners, EP PerMed will not only significantly support
the transnational development of personalised medicine approaches
over the next ten years, but also their successful translation into
clinical practice. A preliminary announcement for the first joint
transnational call for proposals has now been published.
"The
concept of personalised medicine combines biomedical research and
other disciplines with the use of cutting-edge technologies. The
resulting increasing number of personalised therapies enables us to
better understand diseases and treat them more precisely, while at
the same time reducing unwanted side effects," says Dr Wolfgang
Ballensiefen, who is responsible for coordinating the partnership at
the German Aerospace Center’s project management agency, DLR
Projektträger. "In addition, personalised medicine aims at a
specific and early diagnosis of diseases, which enables
individualised prognoses and ultimately early and targeted treatment
or prevention."
The
European Partnership for Personalised Medicine brings together
ministries, funding organisations and research institutes from 24
countries and 10 European regions. EP PerMed builds on the results
and experience of several international initiatives and projects in
the field of personalised medicine, as well as more than 15 years of
successful collaboration among many of the partners involved. Over
the next ten years (2023-2033), most of EP PerMed’s budget will be
available for funding of research projects and the implementation of
personalised medicine approaches.
The
now announced 1st EP PerMed call will
aim to fund research that fosters the identification or validation of
targets for personalised medicine approaches. Applicants must combine
the research on new and advanced targets with companion biomarker
research (companion diagnostics). The final call text will be
published early 2024 and will be based on the Strategic Research and Innovation Agenda for
Personalised Medicine (SRIA PerMed).
As
outlined in the document, additional EP PerMed activities will focus
on actions to support and accelerate innovations in personalised
medicine and its uptake into healthcare systems. These activities
include, for example, partnering events between the research
communities and the private sector, calls for personalised medicine
pilots, particularly in a regional context, and surveys to identify
and contact key players in the healthcare systems and medical
societies.
|
